HRP20231361T1 - Stratifikacija rizika bolesnika s b-prekursorskom akutnom limfoblastičnom leukemijom - Google Patents
Stratifikacija rizika bolesnika s b-prekursorskom akutnom limfoblastičnom leukemijom Download PDFInfo
- Publication number
- HRP20231361T1 HRP20231361T1 HRP20231361TT HRP20231361T HRP20231361T1 HR P20231361 T1 HRP20231361 T1 HR P20231361T1 HR P20231361T T HRP20231361T T HR P20231361TT HR P20231361 T HRP20231361 T HR P20231361T HR P20231361 T1 HRP20231361 T1 HR P20231361T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- cdr
- subject
- bispecific single
- chain antibody
- Prior art date
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 238000013517 stratification Methods 0.000 title 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 6
- 229960003008 blinatumomab Drugs 0.000 claims 2
- 210000003969 blast cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
Claims (4)
1. CD19xCD3 bispecifično jednolančano protutijelo za upotrebu u postupku za liječenje pedijatrijske prekursorske B-stanične ALL kod subjekta, pri čemu navedeni subjekt je subjekt koji ima količinu od najmanje 20% blastnih stanica na 200 prebrojanih stanica koštane srži u uzorku koštane srži iz navedenog subjekta.
2. Bispecifično jednolančano protutijelo za upotrebu prema zahtjevu 1, naznačeno time što navedeno CD19xCD3 bispecifično jednolančano protutijelo sadrži
(a) anti-CD3 CDR-ove teškog lanca prikazane kao CD3 CDR-H1 u SEQ ID NO: 11 (RYTMH), poželjnije u SEQ ID NO: 11 (GYTFTRYTMH), CD3 CDR-H2 u SEQ ID NO: 12 (YINPSRGYTNYNQKFKD) i CD3 CDR-H3 u SEQ ID NO: 13 (YYDDHYCLDY); i/ili
(b) anti-CD3 CDR-ove lakog lanca prikazane kao CD3 CDR-L1 u SEQ ID NO: 14 (RASSSVSYMN), CD3 CDR-L2 u SEQ ID NO: 15 (DTSKVAS) i CD3 CDR-L3 u SEQ ID NO: 16 (QQWSSNPLT); i/ili
(c) anti-CD19 CDR-ove teškog lanca prikazane kao CD19 CDR-H1 u SEQ ID NO: 17 (SYWMN), poželjnije u SEQ ID NO: 17 (GYAFSSYWMN), CD19 CDR-H2 u SEQ ID NO: 18 (QIWPGDGDTNYNGKFKG) i CD19 CDR-H3 u SEQ ID NO: 19 (RETTTVGRYYYAMDY); i/ili
(d) anti-CD19 CDR-ove lakog lanca prikazane kao CD19 CDR-L1 u SEQ ID NO: 20 (KASQSVDYDGDSYLN), CD19 CDR-L2 u SEQ ID NO: 21 (DASNLVS) i CD19 CDR-L3 u SEQ ID NO: 22 (QQSTEDPWT).
3. Bispecifično jednolančano protutijelo za upotrebu prema zahtjevu 1 ili 2, naznačeno time što je navedeno CD19xCD3 bispecifično jednolančano protutijelo blinatumomab (AMG 103).
4. Bispecifično jednolančano protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 3, naznačeno time što je navedeni subjekt ljudski subjekt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005560P | 2014-05-30 | 2014-05-30 | |
| EP18213926.1A EP3531133B1 (en) | 2014-05-30 | 2015-05-20 | Risk-stratification of b-precursor acute lymphoblastic leukemia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231361T1 true HRP20231361T1 (hr) | 2024-02-16 |
Family
ID=53284315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231361TT HRP20231361T1 (hr) | 2014-05-30 | 2015-05-20 | Stratifikacija rizika bolesnika s b-prekursorskom akutnom limfoblastičnom leukemijom |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11079381B2 (hr) |
| EP (3) | EP3149480B1 (hr) |
| AU (1) | AU2015265578B2 (hr) |
| CA (1) | CA2948771C (hr) |
| CY (1) | CY1122600T1 (hr) |
| DK (2) | DK3149480T3 (hr) |
| ES (2) | ES2715679T3 (hr) |
| FI (1) | FI3531133T3 (hr) |
| HR (1) | HRP20231361T1 (hr) |
| HU (2) | HUE042407T2 (hr) |
| LT (2) | LT3149480T (hr) |
| PL (2) | PL3149480T3 (hr) |
| PT (2) | PT3531133T (hr) |
| RS (1) | RS64773B1 (hr) |
| SI (2) | SI3531133T1 (hr) |
| TR (1) | TR201903548T4 (hr) |
| WO (1) | WO2015181683A1 (hr) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| CN100509850C (zh) | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物 |
| DK1976886T3 (en) | 2005-12-16 | 2015-03-02 | Amgen Res Munich Gmbh | Means and methods for the treatment of tumor diseases |
| AU2007248019B2 (en) | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| SI2155783T1 (sl) | 2007-04-03 | 2013-10-30 | Amgen Research (Munich) Gmbh | Medvrstno specifiäśna cd3-epsilon vezavna domena |
| US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
| TR201816277T4 (tr) | 2007-04-03 | 2018-11-21 | Amgen Res Munich Gmbh | Çapraz-tür-spesifik bağlama alanı. |
| RU2536940C2 (ru) | 2008-11-07 | 2014-12-27 | Эмджен Рисерч(Мьюник) ГмбХ | Новое лечение острого лимфобластного лейкоза |
| DK2344539T3 (en) | 2008-11-07 | 2015-05-04 | Amgen Res Munich Gmbh | Treatment of pediatric acute lymphoblastic leukemia |
| RU2548746C2 (ru) | 2009-10-27 | 2015-04-20 | Эмджен Рисерч (Мьюник), ГмбХ | Режим дозирования для введения биспецифичного антитела cd19×cd3 |
| JP6276175B2 (ja) | 2011-04-28 | 2018-02-07 | アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
-
2015
- 2015-05-20 HU HUE15727072A patent/HUE042407T2/hu unknown
- 2015-05-20 PL PL15727072T patent/PL3149480T3/pl unknown
- 2015-05-20 SI SI201531975T patent/SI3531133T1/sl unknown
- 2015-05-20 LT LTEP15727072.9T patent/LT3149480T/lt unknown
- 2015-05-20 TR TR2019/03548T patent/TR201903548T4/tr unknown
- 2015-05-20 US US15/313,136 patent/US11079381B2/en active Active
- 2015-05-20 HR HRP20231361TT patent/HRP20231361T1/hr unknown
- 2015-05-20 WO PCT/IB2015/053705 patent/WO2015181683A1/en active Application Filing
- 2015-05-20 PT PT182139261T patent/PT3531133T/pt unknown
- 2015-05-20 ES ES15727072T patent/ES2715679T3/es active Active
- 2015-05-20 PL PL18213926.1T patent/PL3531133T3/pl unknown
- 2015-05-20 DK DK15727072.9T patent/DK3149480T3/en active
- 2015-05-20 EP EP15727072.9A patent/EP3149480B1/en not_active Revoked
- 2015-05-20 EP EP18213926.1A patent/EP3531133B1/en active Active
- 2015-05-20 SI SI201530653T patent/SI3149480T1/sl unknown
- 2015-05-20 AU AU2015265578A patent/AU2015265578B2/en active Active
- 2015-05-20 PT PT15727072T patent/PT3149480T/pt unknown
- 2015-05-20 FI FIEP18213926.1T patent/FI3531133T3/fi active
- 2015-05-20 EP EP23192350.9A patent/EP4303585A3/en active Pending
- 2015-05-20 RS RS20230997A patent/RS64773B1/sr unknown
- 2015-05-20 ES ES18213926T patent/ES2961565T3/es active Active
- 2015-05-20 CA CA2948771A patent/CA2948771C/en active Active
- 2015-05-20 LT LTEP18213926.1T patent/LT3531133T/lt unknown
- 2015-05-20 HU HUE18213926A patent/HUE063648T2/hu unknown
- 2015-05-20 DK DK18213926.1T patent/DK3531133T3/da active
-
2019
- 2019-03-13 CY CY20191100304T patent/CY1122600T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3531133T (lt) | 2023-11-10 |
| AU2015265578B2 (en) | 2021-09-02 |
| WO2015181683A4 (en) | 2016-02-04 |
| WO2015181683A1 (en) | 2015-12-03 |
| CY1122600T1 (el) | 2021-03-12 |
| EP3531133B1 (en) | 2023-08-23 |
| EP3149480A1 (en) | 2017-04-05 |
| ES2715679T3 (es) | 2019-06-05 |
| SI3531133T1 (sl) | 2023-12-29 |
| EP3149480B1 (en) | 2018-12-26 |
| DK3149480T3 (en) | 2019-04-01 |
| HUE063648T2 (hu) | 2024-01-28 |
| PL3531133T3 (pl) | 2024-01-29 |
| FI3531133T3 (fi) | 2023-11-02 |
| EP3531133A1 (en) | 2019-08-28 |
| PT3149480T (pt) | 2019-03-21 |
| EP4303585A3 (en) | 2024-01-24 |
| DK3531133T3 (da) | 2023-11-06 |
| CA2948771A1 (en) | 2015-12-03 |
| US11079381B2 (en) | 2021-08-03 |
| CA2948771C (en) | 2023-10-17 |
| LT3149480T (lt) | 2019-04-25 |
| PL3149480T3 (pl) | 2019-06-28 |
| EP4303585A2 (en) | 2024-01-10 |
| TR201903548T4 (tr) | 2019-04-22 |
| SI3149480T1 (sl) | 2019-05-31 |
| AU2015265578A1 (en) | 2016-11-17 |
| RS64773B1 (sr) | 2023-11-30 |
| PT3531133T (pt) | 2023-11-07 |
| HUE042407T2 (hu) | 2019-06-28 |
| US20170122947A1 (en) | 2017-05-04 |
| ES2961565T3 (es) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2017528476A5 (hr) | ||
| JP2013198490A5 (hr) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| ECSP18043564A (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MX2019013387A (es) | Dominio de union a antigeno. | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| CL2020002223A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| JP2016512551A5 (hr) | ||
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2015535828A5 (hr) | ||
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| JP2014205674A5 (hr) | ||
| PE20181051A1 (es) | Anticuerpo anti-epha4 |